Although the stomach is often perceived as a crude, food-grinding, muscular bag, scientific breakthroughs have shown us that in the case of the stomach there is more than meets the eye. The endocrine function of the stomach is mainly exerted through the actions of ghrelin, an acylated peptide hormone that is the first known and so far most extensively studied endogenous orexigenic substance. The satiety-hunger balance is kept in check by many anorexigenic gut hormones among which is the deacylated form of ghrelin - desacyl ghrelin. The interplay of gut hormones affects the brain directly, as most gut hormones cross the blood-brain barrier and bind to their respective receptors in the central nervous system. Other hormones like obestatin and nesfatin are secreted from the stomach along with ghrelin, yet their physiological function is to be elucidated. The importance of the satiety-hunger balance can be seen in its most typical derangement - obesity. Some studies imply that ghrelin, along with other gut hormones, plays an important part in the pathophysiology of obesity. More importantly, it seems that the mechanisms by which bariatric surgery procedures induce weight loss are primarily based on changing the gut hormone levels, including ghrelin. If proven, ghrelin antagonists could be the renaissance of pharmacological obesity treatment.

Keywords:
Gut hormones, Gut-brain interplay, Ghrelin, Obestatin, Nesfatin, Obesity
1.
Stengel A, Taché Y: Gastric peptides and their regulation of hunger and satiety. Curr Gastroenterol Rep 2012;14:480-488.
2.
Murphy KG, Bloom SR: Gut hormones and the regulation of energy homeostasis. Nature 2006;444:854-859.
3.
Näslund E, Hellström PM: Appetite signaling: from gut peptides and enteric nerves to brain. Physiol Behav 2007;92:256-262.
4.
Vincent RP, Ashrafian H, le Roux CW: Mechanisms of disease: the role of gastrointestinal hormones in appetite and obesity. Nat Clin Pract Gastroenterol Hepatol 2008;5:268-277.
5.
Ahima RS, Antwi DA: Brain regulation of appetite and satiety. Endocrinol Metab Clin North Am 2008;37:811-823.
6.
Stanley S, Wynne K, McGowan B, Bloom S: Hormonal regulation of food intake. Physiol Rev 2005;85:1131-1158.
7.
Schwartz GJ: Integrative capacity of the caudal brainstem in the control of food intake. Philos Trans R Soc Lond B Biol Sci 2006;361:1275-1280.
8.
Chaudhri OB, Wynne K, Bloom SR: Can gut hormones control appetite and prevent obesity? Diabetes Care 2008;31(suppl 2):S284-S289.
9.
Bewick GA: Bowels control brain: gut hormones and obesity. Biochem Med (Zagreb) 2012;22:283-297.
10.
Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG: Central nervous system control of food intake. Nature 2000;404:661-671.
11.
Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ: The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 2001;25:S63-S67.
12.
Ellacott KL, Cone RD: The role of the central melanocortin system in the regulation of food intake and energy homeostasis: lessons from mouse models. Philos Trans R Soc Lond B Biol Sci 2006;361:1265-1274.
13.
Badman MK, Flier JS: The gut and energy balance: visceral allies in the obesity wars. Science 2005;307:1909-1914.
14.
Schwartz MW, Woods SC, Seeley RJ, Barsh GS, Baskin DG, Leibel RL: Is the energy homeostasis system inherently biased toward weight gain? Diabetes 2003;52:232-238.
15.
Leibel RL, Rosenbaum M, Hirsch J: Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995;332:621-628.
16.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone releasing acylated peptide from stomach. Nature 1999;402:656-560.
17.
Takaya K, Ariyasu H, Kanamoto N, Iwakura H, et al: Ghrelin strongly stimulates growth hormone (GH) release in humans. J Clin Endocrinol Metab 2000;85:4908-4911.
18.
Perboni S, Inui A: Appetite and gastrointestinal motility: role of ghrelin-family peptides. Clin Nutr 2010;29:227-234.
19.
Kirchner H, Heppner KM, Tschöp MH: The role of ghrelin in the control of energy balance. Handb Exp Pharmacol 2012;209:161-184.
20.
Müller TD, Tschöp MH: Ghrelin - a key pleiotropic hormone-regulating systemic energy metabolism. Endocr Dev 2013;25:91-100.
21.
Dezaki K: Ghrelin function in insulin release and glucose metabolism. Endocr Dev 2013;25:135-143.
22.
Delhanty PJ, van der Eerden BC, van Leeuwen JP: Ghrelin and bone. Biofactors, Epub ahead of print.
23.
Muccioli G, Lorenzi T, Lorenzi M, Ghè C, Arnoletti E, Raso GM, Castellucci M, Gualillo O, Meli R: Beyond the metabolic role of ghrelin: a new player in the regulation of reproductive function. Peptides 2011;32:2514-2521.
24.
Michalakis K, Mintziori G, Kaprara A, Tarlatzis BC, Goulis DG: The complex interaction between obesity, metabolic syndrome and reproductive axis: a narrative review. Metabolism 2013;62:457-478.
25.
Asakawa A, Ataka K, Fujino K, Chen CY, Kato I, Fujimiya M, Inui A: Ghrelin family of peptides and gut motility. J Gastroenterol Hepatol 2011;26(suppl 3):73-74.
26.
Tesauro M, Schinzari F, Caramanti M, Lauro R, Cardillo C: Cardiovascular and metabolic effects of ghrelin. Curr Diabetes Rev 2010;6:228-235.
27.
Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, et al: Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001;86:4753-4658.
28.
Jeon TY, Lee S, Kim HH, Kim YJ, Son HC, Kim DH, Sim MS: Changes in plasma ghrelin concentration immediately after gastrectomy in patients with early gastric cancer. J Clin Endocrinol Metab 2004;89:5392-5396.
29.
Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, et al: Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000;141:4255-4261.
30.
Date Y, Nakazato M, Hashiguchi S, Dezaki K, Mondal MS, Hosoda H, Kojima M, et al: Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 2002;51:124-129.
31.
Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, Korbonits M: The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002;87:2988.
32.
Barreiro ML, Gaytan F, Caminos JE, Pinilla L, Casanueva FF, Aguilar E, Dieguez C, Tena-Sempere M: Cellular location and hormonal regulation of ghrelin expression in rat testis. Biol Reprod 2002;67:1768-1776.
33.
Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, et al: Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 1997;48:23-29.
34.
Kamegai J, Tamura H, Shimizu T, et al: Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology 2000;141:4797-4800.
35.
Korbonits M, Bustin SA, Kojima M, et al: The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:881-887.
36.
Papotti M, Ghe C, Cassoni P, et al: Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 2000;85:3803-3807.
37.
Li Z, Li Y, Zhang W: Ghrelin receptor in energy homeostasis and obesity pathogenesis. Prog Mol Biol Transl Sci 2013;114:45-87.
38.
Kojima M, Kangawa K: Ghrelin: from gene to physiological function. Results Problems Cell Differ 2010;50:185-205.
39.
Kaiya H, Miyazato M, Kangawa K, Peter RE, Unniappan S: Ghrelin: a multifunctional hormone in non-mammalian vertebrates. Comp Biochem Physiol 2008;149:109-128.
40.
Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL: Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008;132:387-396.
41.
Gutierrez JA, Solenberg PJ, Perkins DR, Willency JA, Knierman MD, Jin Z, et al: Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci USA 2008;105:6320-5325.
42.
Shlimun A, Unniappan S: Ghrelin O-acyl transferase: bridging ghrelin and energy homeostasis. Int J Pept 2011;2011:217957.
43.
Ohgusu H, Shirouzu K, Nakamura Y, et al: Ghrelin O-acyltransferase (GOAT) has a preference for n-hexanoyl-CoA over n-octanoyl-CoA as an acyl donor. Biochem Biophys Res Commun 2009;386:153-158.
44.
Lim CT, Kola B, Korbonits M: The ghrelin/GOAT/GHS-R system and energy metabolism. Rev Endocr Metab Disord 2011;12:173-186.
45.
van der Klaauw AA, Keogh JM, Henning E, Blackwood A, Haqq AM, Purnell JQ, Farooqi IS: Postprandial total ghrelin suppression is modulated by melanocortin signaling in humans. J Clin Endocrinol Metab 2013;98:E288-E292.
46.
van Thuijl H, Kola B, Korbonits M: Appetite and metabolic effects of ghrelin and cannabinoids: involvement of AMP-activated protein kinase. Vitam Horm 2008;77:121-148.
47.
Verhulst PJ, Janssen S, Tack J, Depoortere I: Role of the AMP-activated protein kinase (AMPK) signaling pathway in the orexigenic effects of endogenous ghrelin. Regul Pept 2012;173:27-35.
48.
Banks WA, Tschop M, Robinson SM, Heiman ML: Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 2002;302:822-827.
49.
Date Y, Murakami N, Toshinai K, Matsukura S, Niijima, et al: The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002;123:1120-1128.
50.
Dornonville de la Cour C, Lindqvist A, Egecioglu E, et al: Ghrelin treatment reverses the reduction in weight gain and body fat in gastrectomised mice. Gut 2005;54:907-913.
51.
le Roux CW, Neary NM, Halsey TJ, Small CJ, Martinez-Isla AM, Ghatei MA, Theodorou NA, Bloom SR: Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab 2005;90:4521-4524.
52.
del Parigi A, Tschop M, Heiman ML, Salbe A, et al: High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metabol 2002;87:5461-5464.
53.
Cummings DE, Purnell JQ, Frayo RS, Schmidova K, et al: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:1714-1719.
54.
Tschop M, Wawarta R, Riepl RS, et al: Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001;24:RC19-RC21.
55.
Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D: Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without timeand food-related cues. Am J Physiol Endocrinol Metab 2004;287:E297-E304.
56.
Murray CD, le Roux CW, Gouveia C, Bassett P, Ghatei MA, Bloom SR, Emmanuel AV, Gabe SM: The effect of different macronutrient infusions on appetite, ghrelin and peptide YY in parenterally fed patients. Clin Nutr 2006;25:626-633.
57.
Feinle-Bisset C, Patterson M, Ghatei MA, Bloom SR, Horowitz M: Fat digestion is required for the suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid. Am J Physiol Endocrinol Metab 2005;289:E948-5E953.
58.
Foster-Schubert KE, Overduin J, Prudom CE, et al: Acyl and total ghrelin are suppressed strongly by ingested proteins, weakly by lipids, and biphasically by carbohydrates. J Clin Endocrinol Metab 2008;93:1971-1979.
59.
Akamizu T, Takaya K, Irako T, et al: Pharmacokinetics, safety and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocrinol 2004;150:447-455.
60.
Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR: Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992.
61.
Malik S, McGlone F, Bedrossian D, Dagher A: Ghrelin modulates brain activity in areas that control appetitive behavior. Cell Metab 2008;7:400-409.
62.
Kroemer NB, Krebs L, Kobiella A, Grimm O, et al: Fasting levels of ghrelin covary with the brain response to food pictures. Addict Biol 2013;18:855-862.
63.
Schüssler P, Kluge M, Yassouridis A, Dresler M, Uhr M, Steiger A: Ghrelin levels increase after pictures showing food. Obesity (Silver Spring) 2012;20:1212-1217.
64.
Schellekens H, Dinan TG, Cryan JF: Ghrelin at the interface of obesity and reward. Vitam Horm 2013;91:285-323.
65.
Schellekens H, Finger BC, Dinan TG, Cryan JF: Ghrelin signalling and obesity: at the interface of stress, mood and food reward. Pharmacol Ther 2012;135:316-326.
66.
Karra E, Batterham RL: The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol 2010;316:120-128.
67.
Stengel A, Taché Y: Interaction between gastric and upper small intestinal hormones in the regulation of hunger and satiety: ghrelin and cholecystokinin take the central stage. Curr Protein Pept Sci 2011;12:293-304.
68.
Theander-Carrillo C, Wiedmer P, Cettour-Rose P, Nogueiras R, Perez-Tilve D, Pfluger P, Castaneda TR, Muzzin P, Schürmann A, Szanto I, Tschöp MH, Rohner-Jeanrenaud F: Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 2006;116:1983-1993.
69.
Wortley KE, del Rincon JP, Murray JD, Garcia K, et al: Absence of ghrelin protects against early-onset obesity. J Clin Invest 2005;115:3573-3578.
70.
Tolle V, Kadem M, Bluet-Pajot MT, Frere D, et al: Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J Clin Endocrinol Metab 2003;88:109-116.
71.
Nagaya N, Uematsu M, Kojima M, et al: Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001;104:2034-2038.
72.
Shimizu Y, Nagaya N, Isobe T, Imazu M, et al: Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 2003;9:774-778.
73.
Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-1630.
74.
Ravussin E, Tschop M, Morales S, Bouchard C, Heiman ML: Plasma ghrelin concentration and energy balance: overfeeding and negative energy balance studies in twins. J Clin Endocrinol Metab 2001;86:4547-4551.
75.
Leydi HJ, Gardneer JK, Frye BR, et al: Circulating ghrelin is sensitive to changes in body weight during a diet and exercise program in normal-weight young women. J Clin Endocrinol Metab 2004;89:1319-1324.
76.
Tschop M, Weyer C, Tataranni PA, et al: Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50:707-709.
77.
Hellstrom M, Geliebter A, Naslund E, Schmidt PT, Yahav EK, Hashim SA, Yeomans MR: Peripheral and central signals in the control of eating in normal, obese and binge-eating human subjects. Br J Nutr 2004;92:S47-S57.
78.
Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, Basdevant A, Weigle DS: Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 2002;8:643-644.
79.
Tritos NA, Mun E, Betkau A, et al: Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res 2003;11:919-924.
80.
Cummings DE, Shannon MH: Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab 2003;88:2999-3002.
81.
Hosoda H, Kojima M, Matsuo H, Kangawa K: Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 2000;279:909-913.
82.
Delhanty PJ, Neggers SJ, van der Lely AJ: Desacyl ghrelin: a metabolically active peptide. Endocr Dev 2013;25:112-121.
83.
Asakawa A, Inui A, Fujimiya M, et al: Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 2005;54:18-24.
84.
Inhoff T, Mönnikes H, Noetzel S, Stengel A, et al: Desacyl ghrelin inhibits the orexigenic effect of peripherally injected ghrelin in rats. Peptides 2008;29:2159-2168.
85.
Kumar R, Salehi A, Rehfeld JF, et al: Proghrelin peptides: desacyl ghrelin is a powerful inhibitor of acylated ghrelin, likely to impair physiological effects of acyl ghrelin but not of obestatin: a study of pancreatic polypeptide secretion from mouse islets. Regul Pept 2010;164:65-70.
86.
Zhang JV, Ren P-G, Avsian-Kretchmer O, Luo C-W, Rauch R, Klein C, Hsueh AJ: Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005;310:996-999.
87.
Lauwers E, Landuyt B, Arckens L, Schoofs L, Luyten W: Obestatin does not activate orphan G protein-coupled receptor GPR39. Biochem Biophys Res Commun 2006;351:21-25.
88.
Tremblay F, Perreault M, Klaman LD, Tobin JF, Smith E, Gimeno RE: Normal food intake and body weight in mice lacking the G protein-coupled receptor GPR39. Endocrinology 2007;148:501-506.
89.
Holst B, Egerod KL, Schild E, Vickers SP, Cheetham S, et al: GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 2007;148:13-20.
90.
Chartrel N, Alvear-Perez R, Leprince J, et al: Comment on ‘Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake'. Science 2007;315:766; author reply 766.
91.
Pruszynska-Oszmalek E, Szczepankiewicz D, Hertig I, Skrzypski M, Sassek M, Kaczmarek P, Kolodziejski PA, Mackowiak P, Nowak KW, Strowski MZ, Wojciechowicz T: Obestatin inhibits lipogenesis and glucose uptake in isolated primary rat adipocytes. J Biol Regul Homeost Agents 2013;27:23-33.
92.
Stengel A, Goebel M, Yakubov I, et al: Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009;150:232-238.
93.
Oh-I S, Shimizu H, Satoh T, Okada S, et al: Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443:709-712.
94.
Stengel A, Goebel M, Wang L, et al: Central nesfatin-1 reduces dark-phase food intake and gastric emptying in rats: differential role of corticotropin-releasing factor 2 receptor. Endocrinology 2009;150:4911-4919.
95.
Maejima Y, Sedbazar U, et al: Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metab 2009;10:355-365.
96.
Tsuchiya T, Shimizu H, Yamada M, et al: Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin Endocrinol (Oxf) 2010;73:484-490.
97.
Li Z, Mulholland M, Zhang W: Regulation of gastric nesfatin-1/NUCB2. Curr Pharm Des 2013;19:6981-6985.
98.
Allas S, Abribat T: Clinical perspectives for ghrelin-derived therapeutic products. Endocr Dev 2013;25:157-166.
99.
Patterson M, Bloom SR, Gardiner JV: Ghrelin and appetite control in humans - potential application in the treatment of obesity. Peptides 2011;32:2290-2294.
100.
Zorrilla EP, Iwasaki S, Moss JA, et al: Vaccination against weight gain. Proc Nat Acad Sci USA 2006;103:13226-13231.
101.
Yang J, Zhao TJ, Goldstein JL, Brown MS: Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides. Proc Nat Acad Sci USA 2008;105:10750-10755.
102.
Dezaki K, Yada T: Islet β-cell ghrelin signaling for inhibition of insulin secretion. Methods Enzymol 2012;514:317-331.
103.
Shin A, Camilleri M, Busciglio I, et al: Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 2013;36:41-48.
104.
Neary NM, Small CJ, Wren AM, Lee JL, et al: Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:2832-2836.
105.
Strasser F: Clinical application of ghrelin. Curr Pharm Des 2012;18:4800-4812.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.